• Takeda Pharmaceuticals North America, Incmedical research image by Albert Lozano from Fotolia.com
  
  Takeda Pharmaceuticals Company Limited (TPCL) is Japan's largest and "fastest growing" pharmaceutical company, and specializes in the design of "innovative products" that improve patient health and lifestyle. Takeda Pharmaceuticals North America, Inc (TPNA), a subsidiary of TPCL, provides drugs to treat illnesses such as diabetes, kidney disease, bone and joint diseases, and other chronic diseases. TPCL is also involved in clinical research under Takeda Global Research & Development Center, Inc. TPNA offers medical education grants to fund medical education programs that adhere to TPNA guidelines.
  
  

Areas of Educational Grant Funding

• The TPNA Medical Education Grant is awarded for programs that advance health treatment outcomes and operations. TPNA is particularly interested in programs specializing in therapeutic treatments for depression, anxiety, and metabolic and gastrointestinal diseases. To qualify for funding, metabolic disease-centered programs must focus on therapeutic treatment for gout, hyperuricemia, hypertension, type 2 diabetes or obesity. Gastrointestinal disease-centered programs must focus on therapeutic treatment for chronic constipation, constipation-predominant irritable bowel syndrome, inflammatory bowel syndrome, or gatroesophageal reflux disease. TPNA instructs that applicants with financial needs for programs concerning therapeutic treatment in oncology, apply to Millennium Pharmaceuticals, Inc (MP). As a subsidiary of TPCL, MP operates independently as a "global center" for oncology solutions. As of July, 2010 Takeda is only offering educational funding in the areas of hypertension, inflammatory bowel disease, anemia in chronic kidney disease, gout, and hyperuricemia.
  
  

Educational Grant Requirements

• In order to receive funding from TPNA, certain requirements must be met by the requesting medical education program. First, a program must have a valid need for funding. All requesting programs will be subject to a needs assessment for verification purposes. Second, a program must have "measurable learning objectives" with the intent of advancing and reforming patient health care. Third, a program's instructional and learning strategy or strategies must be effective. Finally, all skills, knowledge and competencies must be verifiable and in accordance with stated learning objectives.
  
  

Application Schedule and Grant Disclaimer

• The application periods for 2010 are Feb. 1 to March 31, with a final notice day of May 7; May 1 to June 30, with a final notice day of Aug. 6; Aug. 1 to Sept. 30, with a final notice day of Nov. 5; and Nov. 1 to Dec. 3, with a final notice day of Feb. 4.
  
  Please note that only medical education grant requests will be considered. Selection of grant recipients will be based on academic and scientific merit, financial discipline, market appeal, ethical principle and conformity with all legal standards. Takeda reserves the right to publicly publish all information pertaining to grant recipients' programs and research.
  
  Takeda Pharmaceuticals North America, Inc.
  
  Medical and Scientific Affairs
  
  Medical Education Department
  
  One Takeda Parkway
  
  Deerfield, IL 60015
  
  1-800-390-1204
  
  takedaeducationalgrants.com